Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Market Access Impact: Multiple Sclerosis (EU5) 2017

Product Code:
596200777
Publication Date:
July 2017
Format:
PowerPoint
Price:
€4945

Market barriers affect nearly 15% of multiple sclerosis prescriptions in the EU5

In the EU5 countries, market barriers affect a modest 15% of multiple sclerosis prescriptions, but they’re giving market share to most of the brands we surveyed. These market share gains go to 7 of the 11 brands we surveyed, putting the market leaders even further ahead. Meanwhile some brands have a bigger problem: doctors aren’t prescribing them at the same rates as other treatments.

Market Access Impact: Multiple Sclerosis (EU5) shows you how widely prescribed your brand is, and reveals how 7 barriers affect your market share. You’ll learn how much share you win and lose, who you take share from, and who gets your lost share.
Based on a survey of 150 neurologists from the key EU5 markets (France, Germany, Italy, Spain and the UK), the report covers 11 major therapies from Genzyme, Biogen, Sanofi, Bayer, Teva, Novartis, Merck Group, and AbbVie/Biogen.

Not your market? Click here to see the US report

Request sample pages

Top Takeaways

  • Barriers affect nearly 15% of prescriptions. Most barriers have a more or less equal overall impact, but each one affects some brands more than others.
  • Most brands gain share. 7 of the 11 surveyed brands lose market gain share because of barriers, and these gains are significant for the leading brands.
  • One brand has a big lead. Despite the fact that this brand is only the sixth most prescribed brand, barriers are proving to be a huge positive as it gains the most share than any other brand.
  • 2 barriers are holding most brands back. All surveyed neurologists opine that they can’t prescribe many of the brands due to patient related issues.
  • Awareness is good for all brands. Very few neurologists haven’t heard of the brands we surveyed, but ‘willingness to try’ data might be surprising for some brands.

Insight into 11 Multiple Sclerosis Drugs

  • Aubagio (teriflunomide; Sanofi)
  • Avonex (interferon beta-1a; Biogen)
  • Betaferon (interferon-beta-1; Bayer)
  • Copaxone (glatiramer acetate; Teva)
  • Gilenya (fingolimod; Novartis)
  • Lemtrada (alemtuzumab; Genzyme)
  • Plegridy (peginterferon beta-1a; Biogen)
  • Rebif (interferon beta-1a; Merck Group)
  • Tecfidera (dimethyl fumarate; Biogen)
  • Tysabri (natalizumab; Biogen)
  • Zinbryta (daclizumab; AbbVie/Biogen)

Exploring Important Market Access Issues

Market Access Impact: Multiple Sclerosis (EU5) explores key issues affecting drug manufacturers. You’ll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don’t, but would consider it?
  • Why don’t doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 neurologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with Parkinson’s disease in the last month

We conducted the survey between July 3rd and 13th, 2017.

MONEY BACK GUARANTEE!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.




customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved